Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas
Equine Veterinary Journal · 2026
DOI: 10.1111/evj.14502 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Equine Veterinary Journal, 2026. Verfasst von Raphael Labens und 15 weiteren Autor:innen. Beteiligte Einrichtung: Charles Sturt University, Wagga Wagga, New South Wales, Australia. Hauptthemen laut MEDLINE: Horse Diseases, Skin Neoplasms, Melanoma, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: QBiotics Group Limited, Qbiotics.
Abstract (Originalsprache)
Background
Intralesional chemotherapeutic administration represents an important treatment option for equine cutaneous neoplasia. Tigilanol‐tiglate (TT), a novel molecule extracted from Fontainea picrosperma , an Australian rainforest plant, is registered for intratumoural treatment of canine MCT, leading to rapid oncosis and tumour slough. Evidence from horses is limited but suggests that efficacy may be similar.
Objectives
To evaluate the response to intratumoural TT treatment in horses with sarcoids (fibroblastic/nodular) and cutaneous melanomas. Study Design Two noncontrolled prospective multicentre clinical trials, one for each of sarcoids and melanomas.
Methods
Cases were enrolled across multiple sites and treated by the same site‐specific clinician with intralesional TT (sarcoids: 0.35 mg/cm 3 ; melanomas: 0.2 mg/cm 3 of tumour volume − T vol ; max dose 2 mg). Quantitative ( T vol regression) and qualitative outcomes (likely tumour free (LTF) per expert opinion) were recorded, and potential determinants of efficacy were assessed using random effects logistic models. A full clinical response was complete T vol regression and a LTF treatment site.
Results
Forty‐one sarcoids and 97 melanomas were enrolled and treated. 73/74% of treated sarcoids/melanomas showed complete T vol regression. 64/61% (sarcoids/melanomas) showed a full clinical response at medians of 546/247 days post final treatment. For both tumour types, this response was dependent on initial tumour volume ( P sarcoids = 0.006; P melanomas
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Charles Sturt University, Wagga Wagga, New South Wales, Australia.
- University of Georgia, Athens, Georgia, USA.
- University of Cambridge, Cambridge, UK.
- Utrecht University, Utrecht, The Netherlands.
- Universitat Autònoma de Barcelona, Barcelona, Spain.
- Swedish University of Agricultural Sciences, Uppsala, Sweden.
ORCID-Profile: Raphael Labens, Corey Saba, Jarred Williams, Anna Hollis, Kerstin Bergvall, Yvonne Elce, Thomas De Ridder, Paul Reddell
Förderung
- QBiotics Group Limited
- Qbiotics
Zitieren
APA
Labens, R., Saba, C., Williams, J., Hollis, A., Ensink, J., Jose-Cunilleras, E., Jordana-Garcia, M., Bergvall, K., Ruppin, M., Condon, F., Spelta, C., Elce, Y., De Ridder, T., Morton, J., McGee, C., & Reddell, P. (2026). Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas. Equine Veterinary Journal. https://doi.org/10.1111/evj.14502
Vancouver
Labens R, Saba C, Williams J, Hollis A, Ensink J, Jose-Cunilleras E, et al. Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas. Equine Veterinary Journal. 2026. doi:10.1111/evj.14502
BibTeX
@article{Labens2026,
author = {Labens, Raphael and Saba, Corey and Williams, Jarred and Hollis, Anna and Ensink, Jos and Jose-Cunilleras, Eduard and Jordana-Garcia, Mireia and Bergvall, Kerstin and Ruppin, Mick and Condon, Frank and Spelta, Caroline and Elce, Yvonne and De Ridder, Thomas and Morton, John and McGee, Cassandra and Reddell, Paul},
title = {Intratumoural tigilanol tiglate in the multicentre treatment of equine sarcoids and cutaneous melanomas},
journal = {Equine Veterinary Journal},
year = {2026},
doi = {10.1111/evj.14502}
}
EUVIMED